This article is more than 5 years old. Information may no longer be current.

Dexamethasone delivery system shows good efficacy in animal study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

An implantable device that delivers a controlled release of dexamethasone effectively suppressed models of intraocular inflammation in a rat study. According to the study authors, the device may have potential for treating uveitis in humans.

Masuhiro Kodama and colleagues at the University of Tokyo Graduate School of Medicine evaluated the Surodex drug delivery system (Oculex Pharmaceuticals) for treating two experimental models of intraocular inflammation in rats: endotoxin-induced uveitis (EIU) and experimental autoimmune uveoretinitis (EAU).

Eyes implanted with the Surodex implant in the EIU experiments showed significantly less inflammation than control eyes. Protein concentration, cell infiltration and myeloperoxidase activity were all greatly reduced.

In the EAU experiment, both eyes of all rats implanted with the Surodex on days 0 through 7 showed either no inflammation or significantly less inflammation.

The study is published in Graefe’s Archive for Clinical and Experimental Ophthalmology.